Mody R, et al. - For patients initiating dulaglutide vs liraglutide or exenatide once a week, researchers assessed adherence (defined as a proportion of days covered ≥80%), persistence, glycemic control and 12-month follow-up costs. Study participants included patients with type 2 diabetes (T2D) and ≥ 1 pharmacy claim for dulaglutide, liraglutide, or exenatide once weekly from the HealthCore Integrated Research Database. According to the results of the present real-world analysis, patients with T2D initiating dulaglutide treatment had significantly higher adherence and persistence than patients initiating liraglutide or exenatide once a week. Patients taking dulaglutide also showed a significantly higher reduction in glycated hemoglobin (HbA1c) vs those taking liraglutide and a higher but nonsignificant reduction in HbA1c vs those with exenatide once a week. Overall, they suggested that dulaglutide might be an important treatment option to improve results in patients with T2D due to the importance of adherence and its role in glycemic control. The mean diabetes-related total costs for dulaglutide vs liraglutide were $16,174 and $16,694, respectively.